Third drug signed off for early access in France
This article was originally published in SRA
Executive Summary
Johnson & Johnson/MSD's Remicade (infliximab) is to be made available to French patients for the unapproved indication of Takayasu's arteritis refractory to conventional drugs, under a temporary use recommendation (RTU)1. Remicade is the third drug to be granted an RTU, a relatively new early-access mechanism, in France.